J M Jiang1, R Kabarriti2, N P Brodin1, N Ohri1, C Guha1, S Kalnicki1, M Garg1. 1. Department of Radiation Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, 111 East 210th Street, Bronx, NY, 10467, USA. 2. Department of Radiation Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, 111 East 210th Street, Bronx, NY, 10467, USA. rkabarri@montefiore.org.
Abstract
PURPOSE: Immunotherapy is now a first-line treatment for metastatic non-small cell lung cancer (NSCLC) and melanomaQuery. It is important to understand the relationship between immunotherapy and radiation to the brain. The aim of this study was to assess the role of stereotactic radiosurgery (SRS) or WBRT in addition to immunotherapy in patients with melanoma or NSCLC metastatic to the brain. METHODS/PATIENTS: Using the National Cancer Database, 2951 patients with NSCLC and 936 patients with melanoma treated with immunotherapy were identified. Patients were classified as having received immunotherapy alone, immunotherapy with SRS, or immunotherapy with whole-brain radiation therapy (WBRT). Kaplan-Meier, multivariate Cox regression analyses, and propensity matching were performed to evaluate the impact of adding SRS to immunotherapy on overall survival (OS). Immortal survival bias was accounted for by only including patients who received radiation before immunotherapy and time zero was defined as the start of immunotherapy. RESULTS: 205(6.9%) and 75(8.0%) patients received immunotherapy with no radiation, 822(27.9%) and 326(34.8%) received SRS and immunotherapy, and 1924(65.2%) and 535(57.2%) received WBRT and immunotherapy for NSCLC and melanoma, respectively. Adding SRS to immunotherapy was associated with improved OS in multivariate analyses (NSCLC HR = 0.81, 95% CI 0.66-0.99, p = 0.044; melanoma HR = 0.63, 95% CI 0.45-0.90, p = 0.011). The addition of WBRT to immunotherapy did not improve OS in patients with melanoma nor NSCLC. CONCLUSIONS: This analysis suggests that treatment with SRS and immunotherapy is associated with improved OS compared to immunotherapy alone for patients with melanoma or NSCLC metastatic to the brain.
PURPOSE: Immunotherapy is now a first-line treatment for metastatic non-small cell lung cancer (NSCLC) and melanomaQuery. It is important to understand the relationship between immunotherapy and radiation to the brain. The aim of this study was to assess the role of stereotactic radiosurgery (SRS) or WBRT in addition to immunotherapy in patients with melanoma or NSCLC metastatic to the brain. METHODS/PATIENTS: Using the National Cancer Database, 2951 patients with NSCLC and 936 patients with melanoma treated with immunotherapy were identified. Patients were classified as having received immunotherapy alone, immunotherapy with SRS, or immunotherapy with whole-brain radiation therapy (WBRT). Kaplan-Meier, multivariate Cox regression analyses, and propensity matching were performed to evaluate the impact of adding SRS to immunotherapy on overall survival (OS). Immortal survival bias was accounted for by only including patients who received radiation before immunotherapy and time zero was defined as the start of immunotherapy. RESULTS: 205(6.9%) and 75(8.0%) patients received immunotherapy with no radiation, 822(27.9%) and 326(34.8%) received SRS and immunotherapy, and 1924(65.2%) and 535(57.2%) received WBRT and immunotherapy for NSCLC and melanoma, respectively. Adding SRS to immunotherapy was associated with improved OS in multivariate analyses (NSCLC HR = 0.81, 95% CI 0.66-0.99, p = 0.044; melanoma HR = 0.63, 95% CI 0.45-0.90, p = 0.011). The addition of WBRT to immunotherapy did not improve OS in patients with melanoma nor NSCLC. CONCLUSIONS: This analysis suggests that treatment with SRS and immunotherapy is associated with improved OS compared to immunotherapy alone for patients with melanoma or NSCLC metastatic to the brain.
Authors: Ricarda Rauschenberg; Johannes Bruns; Julia Brütting; Dirk Daubner; Fabian Lohaus; Lisa Zimmer; Andrea Forschner; Daniel Zips; Jessica C Hassel; Carola Berking; Katharina C Kaehler; Jochen Utikal; Ralf Gutzmer; Patrik Terheyden; Frank Meiss; David Rafei-Shamsabadi; Felix Kiecker; Dirk Debus; Evelyn Dabrowski; Andreas Arnold; Marlene Garzarolli; Marvin Kuske; Stefan Beissert; Steffen Löck; Jennifer Linn; Esther G C Troost; Friedegund Meier Journal: Eur J Cancer Date: 2019-02-07 Impact factor: 9.162
Authors: David S Ettinger; Douglas E Wood; Charu Aggarwal; Dara L Aisner; Wallace Akerley; Jessica R Bauman; Ankit Bharat; Debora S Bruno; Joe Y Chang; Lucian R Chirieac; Thomas A D'Amico; Thomas J Dilling; Michael Dobelbower; Scott Gettinger; Ramaswamy Govindan; Matthew A Gubens; Mark Hennon; Leora Horn; Rudy P Lackner; Michael Lanuti; Ticiana A Leal; Jules Lin; Billy W Loo; Renato G Martins; Gregory A Otterson; Sandip P Patel; Karen L Reckamp; Gregory J Riely; Steven E Schild; Theresa A Shapiro; James Stevenson; Scott J Swanson; Kurt W Tauer; Stephen C Yang; Kristina Gregory; Miranda Hughes Journal: J Natl Compr Canc Netw Date: 2019-12 Impact factor: 11.908
Authors: James E Bates; Christopher G Morris; Michael T Milano; Anamaria R Yeung; Bradford S Hoppe Journal: Radiother Oncol Date: 2019-06-25 Impact factor: 6.280
Authors: Louis Burt Nabors; Jana Portnow; Mario Ammirati; Joachim Baehring; Henry Brem; Nicholas Butowski; Robert A Fenstermaker; Peter Forsyth; Jona Hattangadi-Gluth; Matthias Holdhoff; Steven Howard; Larry Junck; Thomas Kaley; Priya Kumthekar; Jay S Loeffler; Paul L Moots; Maciej M Mrugala; Seema Nagpal; Manjari Pandey; Ian Parney; Katherine Peters; Vinay K Puduvalli; John Ragsdale; Jason Rockhill; Lisa Rogers; Chad Rusthoven; Nicole Shonka; Dennis C Shrieve; Allen K Sills; Lode J Swinnen; Christina Tsien; Stephanie Weiss; Patrick Yung Wen; Nicole Willmarth; Mary Anne Bergman; Anita Engh Journal: J Natl Compr Canc Netw Date: 2017-11 Impact factor: 11.908
Authors: Prashant Gabani; Benjamin W Fischer-Valuck; Tanner M Johanns; Leonel F Hernandez-Aya; Jesse W Keller; Keith M Rich; Albert H Kim; Gavin P Dunn; Clifford G Robinson; Michael R Chicoine; Jiayi Huang; Christopher D Abraham Journal: Radiother Oncol Date: 2018-06-27 Impact factor: 6.280